Dermatology and Therapy最新文献

{"title":"Efficacy and Tolerability of a New Facial 2-Mercaptonicotinoyl Glycine-Containing Depigmenting Serum Versus Hydroquinone 4% over 3-Month Treatment of Facial Melasma.","authors":"Thierry Passeron, Delphine Kerob, Guénaëlle Le Dantec, Anne-Laure Demessant-Flavigny, Alessandro R do Nascimento, Renato Moura, Samir Salah, Mariana Feiges, Erika Fernandez, Andrew Alexis","doi":"10.1007/s13555-025-01473-4","DOIUrl":"https://doi.org/10.1007/s13555-025-01473-4","url":null,"abstract":"<p><strong>Introduction: </strong>Topical treatment with hydroquinone 4% and hydroquinone-based preparations is the gold standard of care for melasma; however, it is limited by complications. 2-Mercaptonicotinoyl glycine (Melasyl™) is a new active ingredient targeting melanin synthesis without impairing the tyrosinase enzyme, with proven efficacy and safety. This study assessed the non-inferiority of a new facial depigmenting serum Mela B3^® (MB3), containing 0.5% 2-mercaptonicotinoyl glycine, versus hydroquinone 4%.</p><p><strong>Methods: </strong>This comparative, non-inferiority, randomized, investigator-blind, parallel-group investigation included adult women with mild-to-severe epidermal or mixed facial melasma. Patients received 3-month treatment with MB3 (twice daily) or hydroquinone 4% (once daily) and applied a broad spectrum SPF 50+/UVA tinted sunscreen (twice daily). Evaluations were conducted at day (D) 0, D28, D56, and D84 of treatment by a dermatologist and the patients. Non-inferiority analysis was performed at D84 on the Modified Melasma Area and Severity Index (mMASI) (non-inferiority margin 1.3). Efficacy assessments included mMASI, Melasma Quality of Life questionnaire (MELASQoL), and Patient Unique Stigmatization Holistic tool in Dermatology (PUSH-D) scores at each visit. Safety and tolerance were evaluated.</p><p><strong>Results: </strong>The study included 109 women (phototypes I-IV; > 80% had phototypes III-IV). At D84, the estimated difference in mMASI score between MB3 and hydroquinone 4% was 0.46 (95% confidence interval - 0.25-1.17). Both groups demonstrated statistically significant improvements on mMASI from D28 versus baseline. The MELASQoL and PUSH-D scores decreased significantly from D28 in both groups (no difference between the groups). Nevertheless, a significant difference in the PUSH-D score was observed at D28 and D56 in favor of MB3. MB3 showed better tolerability versus hydroquinone 4% at D28 with fewer local skin reactions (6.0% versus 21.4%, respectively; p = 0.0286).</p><p><strong>Conclusion: </strong>MB3 shows non-inferior efficacy and better tolerability compared with hydroquinone 4%. MB3 is an effective and well-tolerated alternative option for the topical treatment of melasma.</p><p><strong>Clinical trial registration: </strong>NCT06787846.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Towards a Paradigm Shift in Delivering Hidradenitis Suppurativa Care: a Narrative Review.","authors":"Falk G Bechara, Angelo V Marzano, Antonio Martorell, Hessel H van der Zee, Valeria Jordan M, Nicolas Thomas, Ivette Alarcon, Axel P Villani, Christos C Zouboulis, John R Ingram","doi":"10.1007/s13555-025-01462-7","DOIUrl":"https://doi.org/10.1007/s13555-025-01462-7","url":null,"abstract":"<p><p>Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder characterized by deep-seated nodules, recurrent painful abscesses, and draining tunnels in the intertriginous skin areas that may lead to irreversible tissue damage and scarring. This disfiguring and debilitating disease is also associated with several systemic comorbid disorders, mental health issues, and reduced quality of life. Recent research has significantly advanced our understanding of HS pathogenesis, thereby opening doors to novel treatments. However, challenges persist, such as disease underreporting, diagnostic delays, and a scarcity of evidence-based treatments. Owing to diagnostic delays, the therapeutic \"window of opportunity\" is often missed, contributing to suboptimal outcomes, with the patient receiving treatment only at advanced stages of the disease. The heterogeneity in outcome measures and the relative lack of well-defined disease phenotypes and biomarkers further complicates the management of the disease. Strategies aimed toward early treatment initiation, identifying patient phenotypes or risk factors for rapid disease progression, and timely intervention with biologic therapy could enhance treatment outcomes. This article presents a review of these critical areas and the potential measures that could improve patient care leading to a better quality of life.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of the Efficacy and Safety of Xeligekimab (GR1501) in Patients with Moderate-to-Severe Plaque Psoriasis: A Multicenter, Randomized, Double-Blind Phase II Clinical trial.","authors":"Lin Cai, Chengxin Li, Shanshan Li, Xiaodong Zhang, Gang Wang, Jianbin Yu, Kun Huang, Hong Fang, Yangfeng Ding, Jinyan Wang, Congjun Jiang, Qianjin Lu, Juan Tao, Jianzhong Zhang","doi":"10.1007/s13555-025-01450-x","DOIUrl":"10.1007/s13555-025-01450-x","url":null,"abstract":"<p><strong>Introduction: </strong>Psoriasis is a chronic inflammatory skin disease. This study evaluated the efficacy and safety of xeligekimab (GR1501), a novel anti-interleukin-17A (anti-IL-17A) monoclonal antibody, in Chinese patients with moderate-to-severe plaque psoriasis.</p><p><strong>Methods: </strong>In this multicenter, randomized, double-blind, phase II trial, 199 patients were assigned (1:1:1:1) to receive placebo (n = 49) or xeligekimab 100 mg (n = 50), 150 mg (n = 49), or 200 mg (n = 51) every 4 weeks for 12 weeks. All participants then entered a 40-week extension receiving xeligekimab 200 mg every 4 or 8 weeks. The primary endpoint was a 75% reduction in the Psoriasis Area and Severity Index (PASI 75) at week 12. Secondary endpoints included PASI 75, PASI 90 (≥ 90% improvement), and a static Physician's Global Assessment (sPGA) score of 0/1 (clear/almost clear) at week 52. Safety, pharmacokinetics (PK), and anti-drug antibodies (ADA) were also assessed.</p><p><strong>Results: </strong>At week 12, PASI 75 response rates for the 100, 150, and 200 mg groups were 86.0%, 89.8%, and 88.2%, respectively, versus 2.0% for placebo (P < 0.05). At week 52, PASI 75, PASI 90, and sPGA 0/1 response rates remained high in both 4-week (98.8%, 83.3%, 77.4%) and 8-week (92.9%, 83.3%, 78.6%) groups. No dose-dependent safety issues or ADA positivity were observed.</p><p><strong>Conclusion: </strong>Xeligekimab demonstrated strong efficacy, sustained response, and favorable safety in patients with moderate-to-severe plaque psoriasis.</p><p><strong>Trial registration number: </strong>ChiCTR1800017956.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology and Burden of Pediatric Atopic Dermatitis in China.","authors":"Chien-Chia Chuang, Lydia Braham-Chaouche, Ryan Thomas, Tarek Mnif","doi":"10.1007/s13555-025-01403-4","DOIUrl":"10.1007/s13555-025-01403-4","url":null,"abstract":"<p><strong>Introduction: </strong>We aimed to estimate the prevalence, severity, and burden of pediatric atopic dermatitis (AD) in China.</p><p><strong>Methods: </strong>EPI-CARE China was a cross-sectional online survey that assessed AD in the general pediatric populations (aged 0.5‒17 years) between 21 March 2021 and 5 April 2021 in China. Diagnosis of AD prevalence was based on both International Study of Asthma and Allergies in Childhood criteria and self-reported or parent-reported physician confirmation of ever having had AD. Severity (mild, moderate, and severe) in the preceding week was assessed by patient global assessment. Health-related quality of life (HRQoL) was assessed using established dermatology patient-reported outcomes tools (Infant Dermatitis Quality of Life and Children's Dermatology Life Quality Index). Outcomes included type 2 inflammatory comorbidities and itch, skin pain, and sleep disturbance in the previous 24 h (numeric rating scale [NRS]: 0-10 [no symptoms-worst symptoms]), stratified by age group (aged ≤ 5 years, 6-11 years, and 12-17 years).</p><p><strong>Results: </strong>In 7148 patients, AD prevalence was 3.2% (≤ 5 years, 3.8%; 6-11 years, 4.1%; 12-17 years, 1.7%). Of these, 59.1% (≤ 5 years, 66.1%; 6-11 years, 60.1%; 12-17 years, 39.4%), 38.8% (≤ 5 years, 33.9%; 6-11 years, 38.0%; 12-17 years, 53.1%), and 2.0% (≤ 5 years, 0.0%; 6-11 years, 1.9%; 12-17 years, 7.5%) had mild, moderate, and severe AD, respectively. Patients with moderate AD reported greater impacts on HRQoL than patients with mild AD (too few patients with severe AD provided HRQoL data for comparison). Overall, 90.5% patients reported ≥ 1 atopic comorbid condition. The mean (SD) itch, skin pain, and sleep disturbance NRS values were 5.9 (2.4), 5.6 (2.6), and 5.9 (2.3), respectively.</p><p><strong>Conclusions: </strong>These results demonstrate that AD is associated with substantial patient burden in pediatric patients in China.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"1319-1329"},"PeriodicalIF":3.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12092880/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg-IL PSO (Italian Landscape Psoriasis).","authors":"Mario Valenti, Luciano Ibba, Sara Di Giulio, Luigi Gargiulo, Piergiorgio Malagoli, Anna Balato, Federico Bardazzi, Francesco Loconsole, Martina Burlando, Anna E Cagni, Norma Cameli, Carlo G Carrera, Andrea Carugno, Aldo Cuccia, Paolo Dapavo, Eugenia V Di Brizzi, Valentina Dini, Maria C Fargnoli, Francesca M Gaiani, Claudio Guarneri, Claudia Lasagni, Gaetano Licata, Angelo V Marzano, Matteo Megna, Santo R Mercuri, Alessandra Michelucci, Maria L Musumeci, Diego Orsini, Romina Ortega, Luca Potestio, Luca Rapparini, Simone Ribero, Francesca Satolli, Davide Strippoli, Emanuele Trovato, Marina Venturini, Leonardo Zichichi, Pina Brianti, Antonio Costanzo, Alessandra Narcisi","doi":"10.1007/s13555-025-01416-z","DOIUrl":"10.1007/s13555-025-01416-z","url":null,"abstract":"<p><strong>Introduction: </strong>Tildrakizumab is a monoclonal antibody targeting interleukin (IL)-23 approved for the treatment of moderate-to-severe plaque psoriasis across two different dosages (100 mg and 200 mg). The higher dosage is recommended for patients with a body weight ≥ 90 kg or a high disease burden (Psoriasis Area and Severity Index [PASI] ≥ 16 or the involvement of difficult-to-treat areas). We conducted a 52-week multicenter retrospective study to compare the effectiveness and safety of both dosages and assess their impact on specific patient subgroups.</p><p><strong>Methods: </strong>We enrolled a total of 540 patients with high disease burden or body weight ≥ 90 kg; 177 and 363 were treated with tildrakizumab 200 mg and 100 mg, respectively. The effectiveness was evaluated in terms of PASI 90, PASI 100, and PASI ≤ 2 at weeks 16, 28, and 52. We also performed subanalyses according to the body weight (≥ 90 kg), PASI ≥ 16, prior biologic exposure, involvement of difficult-to-treat areas, and the presence of at least one cardiometabolic comorbidity.</p><p><strong>Results: </strong>After 16 weeks of treatment, a higher proportion of patients in the 200-mg group achieved PASI 90 and PASI 100 compared to those in the 100-mg group (43.5% vs. 34.3% and 36.4% vs. 24.2%, respectively). These results were sustained at 1 year, with PASI 90 and PASI 100 reached by 68.6% and 52.9% of patients in the 200-mg group, respectively, versus 57.3% and 35% in the 100-mg group. All subgroup analyses consistently indicated a trend toward greater effectiveness with tildrakizumab 200 mg, particularly in terms of PASI 90 and PASI 100 achievement at weeks 16 and 52. No differences in the safety profile were observed throughout the study period.</p><p><strong>Conclusion: </strong>Our findings confirm the superior effectiveness of tildrakizumab 200 mg over 100 mg in specific subgroups of patients with a comparable safety profile across the study period.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"1427-1440"},"PeriodicalIF":3.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12092844/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mohs Micrographic Surgery and Improved Survival in Skin Cancer: A Narrative Review.","authors":"Pablo Balado-Simó, Miguel Mansilla-Polo, Daniel Morgado-Carrasco","doi":"10.1007/s13555-025-01410-5","DOIUrl":"10.1007/s13555-025-01410-5","url":null,"abstract":"<p><p>Mohs micrographic surgery (MMS) has been shown to achieve very low recurrence rates in skin cancer, and some studies suggest it may improve survival. We conducted a narrative review to assess the impact of MMS on the survival of patients with various skin cancer subtypes. Some retrospective studies suggest that MMS may enhance survival in patients with head and neck melanoma, lentigo maligna, lentigo maligna melanoma, invasive cutaneous squamous cell carcinoma (cSCC) (especially high-risk cSCC), and high-risk dermatofibrosarcoma protuberans, and, possibly, with certain malignant adnexal tumors as well. It is crucial to take these findings into account so as to appropriately prioritize patients and ensure accessibility of MMS. In both Merkel cell carcinoma and leiomyosarcoma, MMS has not consistently demonstrated improved survival compared with wide excision. Evidence regarding improved survival in extramammary Paget's disease remains limited.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"1283-1306"},"PeriodicalIF":3.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12092895/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Canadian Consensus Guidelines for the Management of Atopic Dermatitis with Topical Therapies.","authors":"Melinda J Gooderham, H Chih-Ho Hong, Charles Lynde, Kim A Papp, Jensen Yeung, Harvey Lui, Yvette Miller-Monthrope, Julien Ringuet, Irina Turchin, Vimal H Prajapati","doi":"10.1007/s13555-025-01386-2","DOIUrl":"10.1007/s13555-025-01386-2","url":null,"abstract":"<p><strong>Introduction: </strong>Atopic dermatitis (AD) is a highly prevalent disease in Canada with significant patient burden. Treatment guidance for topical therapy (the mainstay of AD management), with particular consideration of emerging treatments, may further improve patient care. Here, we aim to provide healthcare professionals with AD treatment recommendations from the perspective of 10 Canadian dermatologists with expertise in managing AD.</p><p><strong>Methods: </strong>The panel of dermatologists conducted a systematic literature review and leveraged their clinical experience to develop generally accepted principles, consensus statements, and a treatment algorithm using an iterative consensus process.</p><p><strong>Results: </strong>The panel collectively developed six generally accepted principles, 10 consensus statements, and a treatment algorithm. The guidance notes that assessment of disease severity should encompass both physician-rated measures and patient-reported outcomes. Disease education, lifestyle-based strategies (e.g., trigger avoidance), and supportive measures (e.g., moisturizers) can help reduce signs and symptoms of AD. Choice of therapy should consider disease-, patient-, and treatment-related factors. Although topical corticosteroids (TCS) are often used as first-line treatment in AD, they should be limited to intermittent short-term use. Noncorticosteroid topical therapies (e.g., topical calcineurin inhibitors; topical phosphodiesterase-4 inhibitors; and topical Janus kinase inhibitors) can be used for widespread involvement of AD according to approved use. Once treatment goals are achieved, noncorticosteroid topical maintenance therapy should continue to prevent flares and reduce the need for TCS.</p><p><strong>Conclusion: </strong>Guidance reflecting the benefits and limitations of topical AD treatments in conjunction with patient understanding of treatment goals supports robust shared decision-making in the management of AD.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"1467-1485"},"PeriodicalIF":3.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12092898/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143972365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Dermatology Life Quality Index Scores in Adults and Adolescents with Alopecia Areata.","authors":"Kent A Hanson, Sergio Vañó-Galván, Andrew Messenger, Helen Tran, Lynne Napatalung, Keith L Davis, Lizzi Esterberg, Ernest H Law","doi":"10.1007/s13555-025-01417-y","DOIUrl":"10.1007/s13555-025-01417-y","url":null,"abstract":"<p><strong>Introduction: </strong>This study assessed Dermatology Life Quality Index (DLQI) scores of patients with alopecia areata (AA) and compared scores between adults and adolescents.</p><p><strong>Methods: </strong>This was a retrospective chart review in France, Germany, Spain, and the UK. Patients with ≥ 50% scalp hair loss (SHL) due to AA and a DLQI score recorded at their index date (first date of ≥ 50% SHL) were included. The DLQI (scale 0-30; higher scores indicate greater impact) assesses the impact of AA on health-related quality of life (QOL). Multivariable linear regression was used to examine the effect of age on DLQI score, adjusting for covariates. Modified Poisson regression analysis was used to estimate relative risks (RRs) between age groups and DLQI categories (none to moderate effect, very large effect, and extremely large effect), adjusting for covariates, including baseline Severity of Alopecia Tool (SALT) score.</p><p><strong>Results: </strong>Overall, 335 patients were included (249 adults, 86 adolescents). At index, adults had a higher mean (SD) SALT score than adolescents (63.7 [15.5] vs 60.4 [12.8]), whereas mean (SD) DLQI scores were higher in adolescents than adults (22.1 [5.3] vs 18.2 [7.5]). Most patients (84%) had DLQI scores indicating a very large or extremely large impact on their lives; this was more pronounced in adolescents than adults (98% vs 80%). In the multilinear model, adolescents had significantly higher DLQI scores than adults (β = 3.51; P < 0.001), indicating a 3.51-point increase in DLQI score associated with being an adolescent. The RR (95% CI) of a DLQI score indicating a very large effect (1.28 [1.07-1.53]) or extremely large effect (1.40 [1.21-1.61]) relative to no or moderate effect was significantly higher for adolescents vs adults.</p><p><strong>Conclusion: </strong>This study demonstrates that, at the time of experiencing ≥ 50% SHL due to AA, both adults and adolescents reported significant impacts on their QOL, with a higher impact on adolescents.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"1543-1553"},"PeriodicalIF":3.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12092309/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Topical Crisaborole for the Treatment of Recalcitrant Palmoplantar Pustulosis: A Case Series.","authors":"Yen-Yi Sung, Tsen-Fang Tsai","doi":"10.1007/s13555-025-01419-w","DOIUrl":"10.1007/s13555-025-01419-w","url":null,"abstract":"<p><p>Palmoplantar pustulosis (PPP) is a chronic, relapsing disease with sterile pustules involving the palms and soles. The pathogenesis of PPP remains unclear and there is currently no standard treatment. We present three cases of recalcitrant PPP treated with topical 2% crisaborole cream in our clinic from October 2024 to February 2025. All of the patients had received skin biopsy to prove their diagnosis and had been treated with various treatments with limited response. After 4 weeks of topical crisaborole, their palmoplantar pustulosis area and severity index decreased from 7.2 to 2.8, 9 to 1.8, and 28.4 to 0, respectively. Given that PPP involves the skin locally, an effective topical treatment may provide a convenient, inexpensive alternative for such patients. The positive response of topical crisaborole observed in our cases also echoes the efficacy of apremilast, a systemic phosphodiesterase 4 (PDE4) inhibitor which successfully treated PPP in other reports, highlighting the potential role of PDE4 in the pathophysiology of PPP. Further studies are needed for a more comprehensive evaluation.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"1579-1585"},"PeriodicalIF":3.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12092904/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143956191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Challenging Psoriasis Clinical Scenarios.","authors":"Linda Stein Gold, Andrew Alexis, Brad P Glick, Mona Shahriari, Eingun James Song, Bruce Strober, Najat M Watch, Melodie Young","doi":"10.1007/s13555-025-01393-3","DOIUrl":"10.1007/s13555-025-01393-3","url":null,"abstract":"<p><p>Psoriasis, a chronic inflammatory skin condition, can have a significant impact on patients' quality of life. Adoption of novel and emerging treatments has significantly improved psoriasis care in clinical practice, but challenges remain. The 'Bridging the Gaps in Challenging Psoriasis' meeting was held in October 2024 to discuss relevant evidence, knowledge gaps, and best practices pertaining to challenging presentations of psoriasis. This report captures important insights and practice impacting guidance gathered from the panel discussion on five topics. The meeting commenced with an in-depth discussion on managing psoriasis in high-impact areas (e.g., scalp, intertriginous regions, nails, and the palms and soles) followed by a discussion on the importance of identifying and addressing common comorbidities associated with psoriasis. The panel explored key considerations and unique challenges when treating psoriasis in patients with darker skin tones ('skin of color') and highlighted the need for tailored therapeutic approaches. A comprehensive dialogue ensued on strategies for managing primary and secondary treatment failures. The session concluded with a concise discussion on the future of psoriasis treatments and pharmacologic therapies currently being developed to manage psoriasis. While discussing various challenging psoriasis scenarios, the dermatology experts emphasized the need to approach psoriasis as a systemic disease and advocated for comprehensive management that addresses both the skin and the broader health of the patient.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"1555-1567"},"PeriodicalIF":3.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12092870/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}